Contineum Therapeutics Total Revenue

The latest total revenue for CTNM is $0 as of June 2026. That compares with $240K in the prior-year period — down 100.0% year over year. That is below the sector sector average of $1.3B. Investors often review this figure alongside Contineum Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CTNM's total revenue moved from $240K to $0 — a 100.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Contineum Therapeutics's operating scale or balance-sheet position.

Against its sector companies, CTNM currently prints $0 for total revenue, while the sector average sits near $1.3B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Contineum Therapeutics's growth, margins, and balance sheet.

A total revenue figure of $0 for CTNM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.3B. Explore the charts below for those layers of context.

After noting CTNM's total revenue ($0), review year-over-year change from $240K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.